A biokinetic model of the systemic distribution and dosimetry of 239Pu in the @entity235 is presented. To achieve maximum consistency with experimental data, known histomorphometric parameters and results of autoradiographic studies were adopted directly. The remaining parameters were determined from retention and excretion measurements by optimization procedures. The beagle model attempts to parallel the @entity1 model as much as possible, but only one liver compartment and one compartment representing other soft tissues were needed to describe the data adequately. The salient features and differences of the biokinetic behavior of 239Pu beagles and @entity1 are compared. Generally the organ retention of the beagle in relation to the lifetime is longer than in @entity1 . This is particularly pronounced in the skeleton. Trabecular deposits of @entity16878 are gradually shifted to cortical sites. For the dosimetric model some additional features disregarded in the @entity1 model were employed. These relate to @entity79 , a gradation of concentrations in marrow, the energy-dependence of absorbed fractions, and the self-absorption in marrow. The model predicts that the contribution of surface deposits to the endosteal dose still exceeds the contributions from bone volume and marrow labels. The average endosteal dose is about eight times and the marrow dose about two times larger than the average skeletal dose. The model provides the basis for the analysis of survival and relative risks.

Biokinetic and dosimetric model of XXXX in the @entity235 .

@entity235 :: ('9615', 'Species') :: ['beagle dog'] @entity1 :: ('9606', 'Species') :: ['humans', 'human'] @entity16878 :: ('MESH:D011005', 'Chemical') :: ['plutonium'] @entity79 :: ('MESH:D001847', 'Disease') :: ['bone volume labels']
@entity16878 :: (MESH:D011005,Chemical) :: ['plutonium']
